Las Vegas, NV -- (SBWIRE) -- 01/04/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: NovaGold Resources Inc. (USA)(NYSEMKT:NG), Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), Myriad Genetics, Inc.(NASDAQ:MYGN), Dynavax Technologies Corporation(NASDAQ:DVAX)
NovaGold Resources Inc. (USA)(NYSEMKT:NG) was a volume gainer of 3.48 million shares and the average volume of the stock remained 1.67 million shares. The stock opened the session at $2.63 and finished at the end of the day at $2.78 and the stock escalated 9.45%.The market capitalization of the stock remained 880.32 million. NovaGold Resources Inc. engages in the exploration and development of mineral properties primarily in Alaska, the United States and British Columbia, Canada. The company primarily explores for gold, silver, copper, zinc, and lead ores. NovaGold Resources Inc. was founded in 1984 and is headquartered in Vancouver, Canada.
For How Long NG will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) exchanged 3.42 million shares and the average volume remained 4.40 million shares. The stock closed the session at $5.87 with the gain of 0.34%. Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Will ARNA Continue To Move Higher? Find Out Here
Myriad Genetics, Inc.(NASDAQ:MYGN) enhanced 3.53% and its closing price was $21.72. The volume of the stock was 3.36 million shares and the average volume remained 2.66 million shares. The market capitalization of the stock remained 1.66 billion. The beta of the stock remained 0.47. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Why Should Investors Buy MYGN After The Recent Gain? Just Go Here and Find Out
Dynavax Technologies Corporation(NASDAQ:DVAX) exchanged 3.24 million shares in the previous trading session, and its average trading remained 5.68 million shares. DVAX advanced 1.53% and it closed the trading at $1.99. The market capitalization of the stock remained 522.62 million. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences.
For How Long DVAX’s Gloss will Attract Investors? Find out via this report
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)